Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
X P Li, Y Li, L Liu, Z T Yuan, Y C Wang, Y C Dong, D S Zhang, J Feng, Y N Chen, S B Wang
Objective: To investigate and verify a novel acute graft versus host disease (aGVHD) prevention protocol in the context of haploidentical hematopoietic stem cell transplantation (haplo-HSCT) . Methods: Patients who underwent haplo-HSCT in our center between January 2022 and December 2022 were included. All patients received reduced doses of cyclophosphamide, Rabbit anti-human tymoglobulin, ruxolitinib, methotrexate, cyclosporine, and MMF to prevent aGVHD. The transplantation outcomes, complications, and survival rate of all patients were investigated...
February 14, 2024: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
#2
JOURNAL ARTICLE
Salem H Alshemmari, Mazyad Almazyad, Ahmed Alsarraf, Anita Kunhikrishnan, Asha M Isaac, Andy Kaempf
INTRODUCTION: The variable clinical course of chronic lymphocytic leukemia (CLL) and the lack of consensus on follow-up and treatment strategies have necessitated a prognostic model for identifying high-risk patients at the time of diagnosis. METHODS: We involved a retrospective analysis of demographic and clinical characteristics of 212 patients diagnosed with Binet stage A CLL and thus eligible for risk stratification by both the International Prognostic Score for Early-stage CLL (IPS-E) and the alternative IPS-E (AIPS-E)...
March 22, 2024: Hematology/oncology and Stem Cell Therapy
#3
JOURNAL ARTICLE
William Shomali, Jason Gotlib
DISEASE OVERVIEW: The eosinophilias encompass a broad range of non-hematologic (secondary or reactive) and hematologic (primary or clonal) disorders with the potential for end-organ damage. DIAGNOSIS: Hypereosinophilia (HE) has generally been defined as a peripheral blood eosinophil count greater than 1.5 × 109 /L, and may be associated with tissue damage. After the exclusion of secondary causes of eosinophilia, diagnostic evaluation of primary eosinophilias relies on a combination of various tests...
March 29, 2024: American Journal of Hematology
#4
Risa Matsumura, Shinji Mochizuki, Yusuke Morishita, Hiroko Hayakawa, Shuhei Karakawa, Hiroshi Kawaguchi, Satoshi Okada, Nobuyuki Hyakuna, Masao Kobayashi
Severe congenital neutropenia (SCN) is characterized by chronic neutropenia with recurrent infections from early infancy and a predisposition to myelodysplastic syndrome/acute myeloid leukemia (AML). Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative treatment for patients with SCN who develop myelodysplastic syndrome/AML. We report an 8-year-old girl with SCN carrying an ELANE mutation that had been refractory to granulocyte colony-stimulating factor. The patient experienced recurrent infections and then developed AML...
February 26, 2024: Hematology Reports
#5
JOURNAL ARTICLE
Julio C Chavez, Ariel Grajales, Jose Sandoval-Sus, Elyce Turba, Lisa Nodzon, Angimar Uriepero-Palma, Mohammad Ammad-Ud-Din, Eva Sahakian, Rami Komrokji, Lubomir Sokol, Frederick L Locke, Bijal Shah, Jeffrey Lancet, Eduardo M Sotomayor, Mohamed A Kharfan-Dabaja, Celeste Bello, Javier Pinilla-Ibarz
BACKGROUND: Advancements in frontline therapy and chemotherapy-sparing treatments in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) have altered the treatment algorithms of this disease. We present a frontline alternative for treatment- naïve (TN) CLL/SLL patients. METHODS: This was a single-center, phase 2 study of high-dose methylprednisolone (HDMP) and ofatumumab with lenalidomide and ofatumumab consolidative therapy for all comers with TN CLL/SLL...
February 13, 2024: Clinical Lymphoma, Myeloma & Leukemia
#6
REVIEW
Cheng-Hsien Wu, Te-Fu Weng, Ju-Pi Li, Kang-Hsi Wu
This comprehensive review delves into the multifaceted roles of mesenchymal stem cells (MSCs) in leukemia, focusing on their interactions within the bone marrow microenvironment and their impact on leukemia pathogenesis, progression, and treatment resistance. MSCs, characterized by their ability to differentiate into various cell types and modulate the immune system, are integral to the BM niche, influencing hematopoietic stem cell maintenance and functionality. This review extensively explores the intricate relationship between MSCs and leukemic cells in acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, and chronic lymphocytic leukemia...
February 21, 2024: International Journal of Molecular Sciences
#7
JOURNAL ARTICLE
B Linder Grønvold, Maryan Mohamed Ali, Tor Å Myklebust, Andrea Lenartova, Mats Remberger, Ingerid Weum Abrahamsen, Geir Erland Tjønnfjord, Anders Eivind Myhre, Yngvar Fløisand, Tobias Gedde-Dahl
Outcomes of 2-year survivours undergoing allo-haematopoietic stem cell transplantation at Oslo University Hospital were retrospectively assessed with the objectives of identification of risk factors for late death as possible means for precautionary measures and interventions to improve long-term survival. 421 patients with haematological malignancy, transplanted between 2005 and 2019, alive and free of disease after 2 years were included with data reported from The OUS-HSCT registry. Median follow-up was 6...
February 2024: EJHaem
#8
JOURNAL ARTICLE
Igor Aurer, Ozren Jakšić, Sandra Bašić-Kinda, Stefan Mrđenović, Slobodanka Ostojić-Kolonić, Dominik Lozić, Hrvoje Holik, Sabina Novaković-Coha, Petra Berneš, Ivan Krečak, Martina Morić-Perić, Marino Narančić, Zdravko Mitrović, Toni Valković
Patients with lymphoid malignancies are at increased risk of death or prolonged infection due to COVID-19. Data on the influence of different antineoplastic treatment modalities on outcomes are conflicting. Anti-CD20 monoclonal antibodies increase the risk of prolonged infection. It is unclear whether this risk is affected by the choice of the antibody (rituximab vs. obinutuzumab). To elucidate the role of antineoplastic therapy on COVID-19 outcomes, KroHem collected data on patients with lymphoid malignancies diagnosed with COVID-19 between October 2020 and April 2021...
January 31, 2024: Biomedicines
#9
Fan-Yu Liao, Yi-Lun Wang, Yu-Chuan Wen, Chia-Chi Chiu, Tsung-Yen Chang, Tang-Her Jaing
Rarely do patients with chronic graft-versus-host disease (cGVHD) experience vitiligo and alopecia areata. Nevertheless, the exact cause of vitiligo and alopecia areata is still not fully understood. The patient experienced a relapse of acute myeloid leukemia (AML) following a second complete remission after undergoing HLA-6/8 mismatched unrelated donor hematopoietic cell transplantation (HCT). Achieving full donor chimerism was successful during the initial stages of the transplant. Nevertheless, the molecular evidence of measurable residual disease remained, prompting the administration of donor lymphocyte infusions (DLI) following a dose-escalation protocol...
January 2024: Curēus
#10
REVIEW
Rory Bennett, John F Seymour
Chronic lymphocytic leukemia (CLL) predominantly affects older adults, characterized by a relapsing and remitting pattern with sequential treatments available for many patients. Identification of progressive/relapsed CLL should prompt close monitoring and early discussion about the next therapies when treatment indications are present. The intervening period represents an opportunity to optimize patient health, including establishing adequate vaccination and surveillance for second primary malignancies, and treating non-CLL-related comorbidities which may impact well-being and CLL therapy...
February 21, 2024: Blood Cancer Journal
#11
Nadine Kutsch, Philipp Gödel, Conrad-Amadeus Voltin, Michael Hallek, Christof Scheid, Peter Borchmann, Udo Holtick
Patients with Richter's transformation of chronic lymphocytic leukemia (CLL) to diffuse large B-cell lymphoma (DLBCL-RT) face a dismal prognosis. A 51-year-old female patient diagnosed with CLL with deletion (17p) in 2009. CLL treatment included chemoimmunotherapy and targeted substances. DLBCL-RT was diagnosed in November 2016. After receiving an allogeneic hematopoietic stem cell transplantation, she relapsed in September 2019 and tisagenlecleucel was infused in December 2019. Cytokine release syndrome grade 2 was treated with two doses of tocilizumab and the patient was started on 140 mg ibrutinib in February 2020...
February 5, 2024: European Journal of Haematology
#12
JOURNAL ARTICLE
Takeshi Okatani, Midori Filiz Nishimura, Yuria Egusa, Sayako Yoshida, Yoshito Nishimura, Asami Nishikori, Tadashi Yoshino, Hidetaka Yamamoto, Yasuharu Sato
Methotrexate (MTX)-associated lymphoproliferative disorder (MTX-LPD) is a lymphoproliferative disorder in patients treated with MTX. The mechanism of pathogenesis is still elusive, but it is thought to be a complex interplay of factors, such as underlying autoimmune disease activity, MTX use, Epstein-Barr virus infection, and aging. The NOTCH genes encode receptors for a signaling pathway that regulates various fundamental cellular processes, such as proliferation and differentiation during embryonic development...
January 28, 2024: Journal of Clinical and Experimental Hematopathology: JCEH
#13
JOURNAL ARTICLE
Joaquín Martínez-López, Javier de la Cruz, Rodrigo Gil-Manso, Víctor Jiménez Yuste, José María Aspa-Cilleruelo, Cristian Escolano Escobar, Javier López-Jiménez, Rafael Duarte, Cristina Jacome Yerovi, José-Ángel Hernández-Rivas, Regina Herráez, Keina Quiroz-Cervantes, Rosalía Bustelos-Rodriguez, Celina Benavente, Pilar Martínez Barranco, Mariana Bastos Oteiro, Adrián Alegre, Jaime Pérez-Oteyza, Elena Ruiz, Eriel Alexis Marcheco-Pupo, Ángel Cedillo, Teresa de Soto Álvarez, Patricia García Ramirez, Rosalía Alonso Trillo, Pilar Herrera, María Luisa Bengochea Casado, Andrés Arroyo Barea, Jose Manuel Martin De Bustamante, Javier Ortiz, María Calbacho Robles, Julio García-Suárez
A greater understanding of clinical trends in COVID-19 outcomes among patients with hematologic malignancies (HM) over the course of the pandemic, particularly the Omicron era, is needed. This ongoing, observational, and registry-based study with prospective data collection evaluated COVID-19 clinical severity and mortality in 1818 adult HM patients diagnosed with COVID-19 between 27 February 2020 and 1 October 2022, at 31 centers in the Madrid region of Spain. Of these, 1281 (70.5%) and 537 (29.5%) were reported in the pre-Omicron and Omicron periods, respectively...
January 16, 2024: Cancers
#14
JOURNAL ARTICLE
Shuchao Qin, Rui Jiang, Luomengjia Dai, Yi Miao, Yeqin Sha, Tonglu Qiu, Chongyang Ding, Zhen Wang, Chuanbing Shi, Yi Xia, Lei Fan, Wei Xu, Jianyong Li, Huayuan Zhu
Indolent lymphoma, including chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and follicular lymphoma (FL), can undergo histological transformation into an aggressive subtype, typically diffuse large B-cell lymphoma (DLBCL). The prognosis of transformed lymphoma is poor. In this study, we reported the efficacy and toxicity of a combination of venetoclax, dose-adjusted rituximab or obinutuzumab, etoposide, prednisone, vincristine, doxorubicin, and cyclophosphamide (VR-DA-EPOCH or VG-DA-EPOCH) in 11 patients with biopsy-proven histology transformation into DLBCL, including 8 patients with RT and 3 with transformed FL (tFL)...
January 22, 2024: Annals of Hematology
#15
Mário Sousa-Pimenta, Ângelo Martins, José Mário Mariz, Pedro Berraondo
INTRODUCTION AND AIMS: Richter syndrome (RS) represents the clonal evolution of chronic lymphocytic leukemia with histological transformation into a high-grade B cell lymphoma (diffuse large B cell lymphoma - DLBCL) or Hodgkin lymphoma. Considering that RS is an uncommon condition with poor prognosis, few high-quality evidence is available. To overcome this unmet need, this meta-analysis aimed to pool efficacy of early clinical trials in Richter syndrome (DLBCL subtype). METHODS: MEDLINE, Scopus and Web of Science were searched up to May of 2023 to identify clinical trials decoying efficacy...
2023: Frontiers in Immunology
#16
JOURNAL ARTICLE
Ran Zhang, Ran Xin, Li-Ping Dou, Yu Jing
Chronic lymphocytic leukemia (CLL) is a low-grade lymphoproliferative tumor that occurs frequently in middle-aged and elderly people. Early and precise intervention can effectively improve the clinical prognosis of CLL patients. In the past, chemotherapy was the main treatment plan. With the development of molecular biology and the continuous advent of immune targeting drugs, targeted drugs targeting B cell receptor signaling pathway have shown high clinical application value in the diagnosis and treatment path of CLL...
December 2023: Zhongguo Shi Yan Xue Ye Xue za Zhi
#17
JOURNAL ARTICLE
Emily E Granger, Morgan Groover, Catherine Harwood, Charlotte M Proby, Emily Karn, Fadi Murad, Chrysalyne D Schmults, Emily S Ruiz
BACKGROUND: Immunosuppression is a known risk factor for the development of cutaneous squamous cell carcinoma (CSCC), especially in solid organ transplant recipients and chronic lymphocytic leukemia. However, this risk is less well defined in autoimmune and inflammatory conditions. OBJECTIVE: Assess the impact that disease-type, duration of immunosuppression, and systemic medications have on CSCC accrual rates, defined as the number of CSCCs a patient develops per year, in autoimmune and inflammatory conditions...
December 1, 2023: Journal of the American Academy of Dermatology
#18
JOURNAL ARTICLE
Marcelina Carretero, Eugenia Villanueva, Erika B Brulc, Franco M Faelo, María A Aguirre, Diego Pérez-de-Arenaza, Cesar A Belziti, Jorge A Arbelbide, Elsa M Nucifora, María L Posadas-Martinez
OBJECTIVE: To describe the evolution of serum free light chains (FLC) in the period between orthotopic heart transplantation (OHT) and autologous stem cell transplantation (ASCT), the hematological response one year after ASCT and chemotherapy and immunosuppressive treatment in patients with AL amyloidosis. METHOD: Case series of consecutive patients diagnosed with AL amyloidosis who received OHT followed by ASCT from the Institutional Registry of Amyloidosis of the Italian Hospital of Buenos Aires, between January 2010 and November 2021...
2023: Archivos de Cardiología de México
#19
JOURNAL ARTICLE
Asami Yamada, Jun-Ichirou Yasunaga, Lihan Liang, Wenyi Zhang, Junya Sunagawa, Shinji Nakaoka, Shingo Iwami, Yasunori Kogure, Yuta Ito, Keisuke Kataoka, Masanori Nakagawa, Masako Iwanaga, Atae Utsunomiya, Ki-Ryang Koh, Toshiki Watanabe, Kisato Nosaka, Masao Matsuoka
Human T-cell leukemia virus type 1 (HTLV-1) establishes chronic infection in humans and induces a T-cell malignancy called adult T-cell leukemia-lymphoma (ATL) and several inflammatory diseases such as HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Persistent HTLV-1 infection is established under the pressure of host immunity, and therefore the immune response against HTLV-1 is thought to reflect the status of the disease it causes. Indeed, it is known that cellular immunity against viral antigens is suppressed in ATL patients compared to HAM/TSP patients...
November 10, 2023: Cancer Science
#20
Savannah S Shumock, William C Temple, Amanda Marinoff, Kathryn Aaronson, Erica Southworth, Simayijiang Xirenayi, Alex G Lee, Stanley G Leung, E Alejandro Sweet-Cordero, Michelle Hermiston, Christine Higham, Elliot Stieglitz
BACKGROUND: The development of tyrosine kinase inhibitors (TKIs) has significantly improved survival rates among patients with Philadelphia chromosome (Ph+) B cell acute lymphoblastic leukemia (B-ALL). Ph-like B-ALL patients lack the BCR::ABL1 translocation but share gene expression profiles with Ph+ B-ALL. The role of TKIs for Ph-like patients pre- and post-hematopoietic stem cell transplantation (HSCT) is not yet clear. CASE: Here we present five cases of pediatric, adolescent, and young adult patients who presented with Ph-like B-ALL or CML in B-ALL blast phase who were treated with personalized TKI regimens pre- and post-HSCT...
November 7, 2023: Cancer reports
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
